Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 16/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | CA1 | P00915 | 3/20 | 1.00 |
| ▸ | CA9 | Q16790 | 3/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | ESR2 | Q92731 | 2/20 | 1.00 |
| ▸ | CA4 | P22748 | 1/20 | 1.00 |
| ▸ | CA6 | P23280 | 1/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.80 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.76 |
| ▸ | RECQL | P46063 | 1/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.73 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emate SCHEMBL14548146 | 1.00 | STS (1.00) | STSCA2CA1CA9ESR1 | |
| Emate SCHEMBL29406834 | 1.00 | STS (1.00) | STSCA2CA1CA9ESR1 | |
| Emate SCHEMBL10062721 | 1.00 | STS (1.00) | STSCA2CA1CA9ESR1 | |
| Emate SCHEMBL6370815 | 1.00 | STS (1.00) | STSCA2CA1CA9ESR1 | |
| SCHEMBL21067318 | 0.91 | STS (0.84) | STSCA2CA1CA9ESR1 | |
| Emate SCHEMBL7164522 | 0.91 | STS (0.86) | STSCA2CA1CA9ESR1 | |
| SCHEMBL17531381 | 0.90 | STS (0.82) | STSCA2CA1CA9ESR1 | |
| SCHEMBL8034430 | 0.90 | STS (0.82) | STSCA2CA1CA9ESR1 | |
| Estrone Sulfuric Acid SCHEMBL2296097 | 0.89 | KDM4E (0.96) | STSCA2CA1CA9ESR1 | |
| Estrone Sulfuric Acid SCHEMBL22846 | 0.89 | STS (1.00) | STSCA2CA1CA9ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025079965-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF PERIODONTAL DISEASES | 주식회사 넥시온바이오텍 | 2025-04-17 | — | — | WO | claimed |
| US-20240082208-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING STEROID SULFATASE INHIBITOR | NEXYON BIOTECH CO., LTD. (KR) | 2024-03-14 | — | — | US | claimed |
| US-20230405020-A1 | SULFATED C19 STEROID HORMONES TO TREAT AND/OR PREVENT PROTEOTOXICITY IN PROTEIN-AGGREGATION DISEASES | UNIVERSIDAD PABLO DE OLAVIDE (ES) | 2023-12-21 | — | — | US | claimed |
| EP-4275683-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING STEROID SULFATASE INHIBITOR | Industry-Academic Cooperation Foundation, Yonsei University (KR) | 2023-11-15 | — | — | EP | claimed |
| CN-116916912-A | Protein toxicity of sulfated C19 steroid hormone for treatment and/or prevention of protein aggregation disease | 帕布罗·德奥拉韦德大学 | 2023-10-20 | — | — | CN | claimed |
| EP-4232021-A1 | SULFATED C19 STEROID HORMONES TO TREAT AND/OR PREVENT PROTEOTOXICITY IN PROTEIN-AGGREGATION DISEASES | Universidad Pablo de Olavide (ES) | 2023-08-30 | — | — | EP | claimed |
| WO-2022149929-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING STEROID SULFATASE INHIBITOR | 연세대학교 산학협력단 | 2022-07-14 | — | — | WO | claimed |
| WO-2022090247-A1 | SULFATED C19 STEROID HORMONES TO TREAT AND/OR PREVENT PROTEOTOXICITY IN PROTEIN-AGGREGATION DISEASES | UNIVERSIDAD PABLO DE OLAVIDE OTRI (ES) | 2022-05-05 | — | — | WO | claimed |
| EP-3939584-A1 | COMPOSITION FOR PREVENTING OR TREATING OBESITY OR LIPID-RELATED METABOLIC DISORDERS | Nexyon Biotech Co., Ltd. (KR) | 2022-01-19 | — | — | EP | claimed |
| US-20210393581-A1 | Composition for Preventing or Treating Obesity or Lipid-Related Metabolic Disorders | NEXYON BIOTECH CO., LTD. (KR) | 2021-12-23 | — | — | US | claimed |
| EP-0982032-A2 | Use of a ring system compound comprising a sulphamic acid ester group for the manufacture of medicaments for the control of oestrogen production | Sterix Limited (GB) | 2000-03-01 | — | — | EP | claimed |
| US-6013642-A | ANTIINFLAMMATORY AGENT | FOULKES ROLAND (GB) | 2000-01-11 | — | — | US | claimed |
| EP-0928609-A2 | Use of sulphamate derivatives as steroid sulphatase inhibitors | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (GB) | 1999-07-14 | — | — | EP | claimed |
| EP-0921130-A2 | Steroid sulphatase inhibitors | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE (GB) | 1999-06-09 | — | — | EP | claimed |
| US-5891620-A | Steroid sulfatase assay | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 1999-04-06 | — | — | US | claimed |
| EP-0791073-A2 | ASSAY | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE (GB) | 1997-08-27 | — | — | EP | claimed |
| US-5616574-A | ANTITUMOR AGENTS FOR BREAST CANCER | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 1997-04-01 | — | — | US | claimed |
| WO-1996015257-A2 | STEROID SULFATASE ASSAY | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (GB) | 1996-05-23 | — | — | WO | claimed |
| EP-0641355-A1 | STEROID SULPHATASE INHIBITORS | IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE (GB) | 1995-03-08 | — | — | EP | claimed |
| WO-1993005064-A1 | STEROID SULPHATASE INHIBITORS | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 1993-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393581-A1 | Composition for Preventing or Treating Obesity or Lipid-Related Metabolic Disorders | LIPC, FABP4, PNLIP | STS 137/4885CA2 2913/4885CA1 3963/4885 |
| US-20230405020-A1 | SULFATED C19 STEROID HORMONES TO TREAT AND/OR PREVENT PROTEOTOXICITY IN PROTEIN-AGGREGATION DISEASES | SERPINA6, HTT, PSMG3 | STS 200/4885CA2 3789/4885CA1 1833/4885 |
| US-20240082208-A1 | ANTIVIRAL PHARMACEUTICAL COMPOSITION COMPRISING STEROID SULFATASE INHIBITOR | STS, SULT2A1, CYP21A2 | STS 1/4885CA2 2843/4885CA1 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.